Militia Capital Management LLC Buys New Position in Abivax SA Sponsored ADR $ABVX

Militia Capital Management LLC bought a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 17,000 shares of the company’s stock, valued at approximately $1,893,000.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE grew its stake in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares in the last quarter. Millennium Management LLC lifted its position in shares of Abivax by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after purchasing an additional 56,235 shares in the last quarter. Woodline Partners LP boosted its holdings in Abivax by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after purchasing an additional 153,788 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Abivax during the second quarter worth $139,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analysts Forecast Growth

ABVX has been the topic of several recent research reports. Citigroup reiterated an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Oddo Bhf restated an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Jefferies Financial Group upgraded Abivax from a “hold” rating to a “buy” rating and raised their price objective for the company from $108.00 to $158.00 in a report on Tuesday, June 30th. Finally, Leerink Partners lifted their target price on Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.50.

Abivax Stock Performance

Shares of ABVX opened at $124.92 on Monday. The company’s fifty day simple moving average is $118.54 and its 200 day simple moving average is $118.41. Abivax SA Sponsored ADR has a 1-year low of $67.09 and a 1-year high of $148.83. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -23.98 and a beta of 1.03.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts forecast that Abivax SA Sponsored ADR will post -3.22 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.